SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Surrozen, Inc. (SRZN) News

Follow Surrozen, Inc. (SRZN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol SRZN Asset equity Sector Markets 90 days 11 Last 28.26 Updated Nov 09, 2026, 09:30 PM UTC Open live news feed Open SRZN chart & news
M Surrozen Reports Q3 2026 Net Loss of $129.7 Million Surrozen reported zero revenue for the third quarter of 2026 and a $129.7 million net loss, including $113.0 million in noncash losses from changes in the fair value of tranche and warrant liabilities. It ended September EQUITY | Nov 09, 2026, 09:30 PM UTC M Surrozen Q3 Net Loss Widens on Higher Non-Cash Charges EQUITY | Nov 09, 2026, 09:17 PM UTC M Surrozen Q3'26 Revenue Estimate Ahead of Results Surrozen is scheduled to report Q3'26 results on November 11; revenue is estimated at 475.00K USD and EPS at (1.10) USD. The report time is not specified. EQUITY | Nov 04, 2026, 12:01 PM UTC L Surrozen FDA clears IND for SZN-8141 in diabetic macular edema REGULATION | Oct 02, 2026, 12:00 PM UTC L Surrozen Price Target Raised to $54.00/Share From $44.00 by HC Wainwright & Co. Ratings actions from Benzinga NEWS | Sep 25, 2026, 12:04 PM UTC H Crude Oil Rises Over 4%; Darden Earnings Miss Views U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 350 points on Thursday. The Dow traded down 0.70% to 51,153.35 while the NASDAQ dipped 0.70% to 26,746.39. The S&P 500 also fell, d LIVE | Sep 24, 2026, 04:02 PM UTC L SRZN DUET study launches for dual VEGF/Wnt therapy in DME A two-part clinical study for a dual VEGF/Wnt molecule in diabetic macular edema will start this year, focusing on safety, efficacy and unique reperfusion endpoints. Initial data is expected in 2027. EQUITY | Sep 10, 2026, 03:04 PM UTC L SRZN: DUET study launches this year to test dual VEGF/Wnt therapy in DME, targeting clinical differentiation The DUET clinical study will launch later this year, evaluating a dual VEGF/Wnt molecule in DME with Vabysmo as comparator, focusing on safety, durability, and unique reperfusion endpoints. Strong preclinical data, robus EQUITY | Sep 10, 2026, 02:08 PM UTC M Surrozen submits IND application for SZN-8141 to treat diabetic macular edema Surrozen says it has submitted an IND application for SZN-8141 for the treatment of diabetic macular edema. EQUITY | Sep 08, 2026, 12:37 PM UTC M Surrozen submits IND application for SZN-8141 in diabetic macular edema Surrozen (SRZN) announced it submitted an IND application for SZN-8141 for the treatment of diabetic macular edema. EQUITY | Sep 08, 2026, 12:31 PM UTC L SRZN - Surrozen to Present at Upcoming Healthcare Investor Conferences SRZN - Surrozen to Present at Upcoming Healthcare Investor Conferences EQUITY | Sep 02, 2026, 08:05 PM UTC L SRZN gets Outperform call and $51 fair value from WBLR Hammerstone MarketTalk reports SRZN is rated Outperform with a $51 fair value at WBLR; no further financial details or catalyst are provided. EQUITY | Aug 20, 2026, 12:29 PM UTC L William Blair initiates SRZN at Outperform William Blair initiates coverage of SRZN with an Outperform rating; no catalyst or valuation details were supplied. EQUITY | Aug 20, 2026, 11:56 AM UTC